Development of a SARS-CoV-2 nucleocapsid specific monoclonal antibody

Terry, James S.; Anderson, Loran B. R.; Scherman, Michael S.; McAlister, Carley; Perera, Rushika; Schountz, Tony; Geiss, Brian J.

doi:10.1016/j.virol.2021.01.003

Cited by 32 publications

(30 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the receptivity of dogs to SARS-CoV-2 infection under experimental conditions [ 27 ], they were unable to transmit the virus [ 7 , 9 , 10 ]. Our results indicated that, in spite of the presence of positive dogs in kennels, there were most probably few infected animals.…”

Section: Discussionmentioning

confidence: 99%

SARS-CoV-2 antibodies seroprevalence in dogs from France using ELISA and an automated western blotting assay

et al. 2021

View full text Add to dashboard Cite

Dogs are occasionally susceptible to SARS-CoV-2, developing few or no clinical signs. Epidemiological surveillance of SARS-CoV-2 in dogs requires testing to distinguish it from other canine coronaviruses. In the last year, significant advances have been made in the diagnosis of SARS-CoV-2, allowing its surveillance in both human and animal populations. Here, using ELISA and automated western blotting (AWB) assays, we performed a longitudinal study on 809 apparently healthy dogs from different regions of France to investigate anti-SARS-CoV-2 antibodies. There were three main groups: (i) 356 dogs sampled once before the pandemic, (ii) 235 dogs sampled once during the pandemic, and (iii) 218 dogs, including 82 dogs sampled twice (before and during the pandemic), 125 dogs sampled twice during the pandemic and 11 dogs sampled three times (once before and twice during the pandemic). Using ELISA, seroprevalence was significantly higher during the pandemic [5.5% (25/453)] than during the pre-pandemic period [1.1% (5/449)]. Among the 218 dogs sampled twice, at least 8 ELISA-seroconversions were observed. ELISA positive pre-pandemic sera were not confirmed in serial tests by AWB, indicating possible ELISA cross-reactivity, probably with other canine coronaviruses. A significant difference was observed between these two serological tests (Q = 88, p = 0.008). A clear correlation was observed between SARS-CoV-2 seroprevalence in dogs and the incidence of SARS-CoV-2 infection in human population from the same area. AWB could be used as a second line assay to confirm the doubtful and discrepant ELISA results in dogs. Our results confirm the previous experimental models regarding the susceptibility of dogs to SARS-CoV-2, suggesting that viral transmission from and between dogs is weak or absent. However, the new variants with multiple mutations could adapt to dogs; this hypothesis cannot be ruled out in the absence of genomic data on SARS-CoV-2 from dogs.

show abstract

Section: Discussionmentioning

confidence: 99%

SARS-CoV-2 antibodies seroprevalence in dogs from France using ELISA and an automated western blotting assay

et al. 2021

View full text Add to dashboard Cite

show abstract

“…1 A), and four main fragments with sizes of the four viral structural proteins (N, M, E and S) were detected 22 . In addition, other fragments were verified in lower concentration that could represent oligomers of the S and N proteins 23 – 25 . Other proteins are probably residual protein content of VERO ATCC-CCL81.4 cells (HCP—host cell protein) which was measured using a specific ELISA and found to be 234.33 ng/mL.…”

Section: Resultsmentioning

confidence: 99%

Anti-SARS-CoV-2 equine F (Ab′)2 immunoglobulin as a possible therapy for COVID-19

Botosso

Jorge

Astray

et al. 2022

Sci Rep

View full text Add to dashboard Cite

The new outbreak of coronavirus disease 2019 (COVID-19) has infected and caused the death of millions of people worldwide. Intensive efforts are underway around the world to establish effective treatments. Immunoglobulin from immunized animals or plasma from convalescent patients might constitute a specific treatment to guarantee the neutralization of the virus in the early stages of infection, especially in patients with risk factors and a high probability of progressing to severe disease. Worldwide, a few clinical trials using anti-SARS-CoV-2 immunoglobulins from horses immunized with the entire spike protein or fragments of it in the treatment of patients with COVID-19 are underway. Here, we describe the development of an anti-SARS-CoV-2 equine F(ab′)2 immunoglobulin using a newly developed SARS-CoV-2 viral antigen that was purified and inactivated by radiation. Cell-based and preclinical assays showed that the F(ab′)2 immunoglobulin successfully neutralizes the virus, is safe in animal models, and reduces the severity of the disease in a hamster model of SARS-CoV-2 infection and disease.

show abstract

“…Furthermore, among pathogenic specimens, blood specimens are easier to obtain and more stable than nasal swabs, stool samples, and so on 12 . According to the recent findings, the SARS‐CoV‐2 N protein is a critical component of the virus replication, involved in the viral particle assembly and the release of viral particles, and a major diagnostic marker of infection and immune protection 13 . And the antibodies to the N protein are the most sensitive diagnostic marker in the serological diagnosis of SARS infection 14 .…”

Section: Discussionmentioning

confidence: 99%

Preparation of highly specific monoclonal antibodies against SARS‐CoV‐2 nucleocapsid protein and the preliminary development of antigen detection test strips

Xie

Ding

et al. 2021

Journal of Medical Virology

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID‐19) is outbreaking all over the world. To help fight this disease, it is necessary to establish an effective and rapid detection method. The nucleocapsid (N) protein of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is involved in viral replication, assembly, and immune regulation and plays an important role in the viral life cycle. Moreover, the N protein also could be a diagnostic factor and potential drug target. Therefore, by synthesizing the N gene sequence of SARS‐CoV‐2, constructing the pET‐28a (+)‐N recombinant plasmid, we expressed the N protein in Escherichia coli and obtained 15 monoclonal antibody (mAbs) against SARS‐CoV‐2‐N protein by the hybridomas and ascites, then an immunochromatographic test strip method detecting N antigen was established. In this study, we obtained 14 high‐titer and high‐specificity monoclonal antibodies, and the test strips exclusively react with the SARS‐CoV‐2‐N protein and no cross‐reactivity with other coronavirus and also recognize the recombinant N protein of Delta (B.1.617.2) variant. These mAbs can be used for the early and rapid diagnosis of SARS‐CoV‐2 infection through serological antigen.

show abstract

Development of a SARS-CoV-2 nucleocapsid specific monoclonal antibody

Cited by 32 publications

References 34 publications

SARS-CoV-2 antibodies seroprevalence in dogs from France using ELISA and an automated western blotting assay

SARS-CoV-2 antibodies seroprevalence in dogs from France using ELISA and an automated western blotting assay

Anti-SARS-CoV-2 equine F (Ab′)2 immunoglobulin as a possible therapy for COVID-19

Preparation of highly specific monoclonal antibodies against SARS‐CoV‐2 nucleocapsid protein and the preliminary development of antigen detection test strips

Contact Info

Product

Resources

About